ライフサイエンスコーパス: mantle-cell lymphoma

1 ngle-agent therapy in relapsed or refractory mantle cell lymphoma.

2 ents with indolent non-Hodgkin's lymphoma or mantle cell lymphoma.

3 VcR-CVAD produced high ORR and CR rates in mantle cell lymphoma.

4 in the clinic to treat multiple myeloma and mantle cell lymphoma.

5 , used for treatment of multiple myeloma and mantle cell lymphoma.

6 elapsing and refractory multiple myeloma and mantle cell lymphoma.

7 formed the treatment of multiple myeloma and mantle cell lymphoma.

8 ma, B-cell chronic lymphocytic leukemia, and mantle cell lymphoma.

9 refractory chronic lymphocytic leukaemia and mantle cell lymphoma.

10 nhibitor PD0332991 in patients with relapsed mantle cell lymphoma.

11 ody) in patients with relapsed or refractory mantle cell lymphoma.

12 s to evaluate this regimen in follicular and mantle cell lymphoma.

13 ent of patients with relapsed and refractory mantle cell lymphoma.

14 e-agent antitumour activity in patients with mantle cell lymphoma.

15 treatment of multiple myeloma and recurring mantle cell lymphoma.

16 for the therapy of multiple myeloma (MM) and mantle cell lymphoma.

17 acytic lymphoma, marginal zone lymphoma, and mantle cell lymphoma.

18 te for the treatment of multiple myeloma and mantle cell lymphoma.

19 as clinical activity in multiple myeloma and mantle cell lymphoma.

20 se for the treatment of multiple myeloma and mantle cell lymphoma.

21 remission (PR) in a patient with refractory mantle cell lymphoma.

22 brutinib in patients with previously treated mantle cell lymphoma.

23 e kinase is a clinically validated target in mantle cell lymphoma.

24 specific tumors, such as Kaposi sarcoma and mantle cell lymphoma.

25 file in patients with relapsed or refractory mantle cell lymphoma.

26 had follicular lymphoma, and one patient had mantle cell lymphoma.

27 ab and idelalisib in relapsed follicular and mantle cell lymphoma.

28 n particular refractory multiple myeloma and mantle cell lymphoma.

29 ated in patients with relapsed or refractory mantle cell lymphoma.

30 ngle-group studies in relapsed or refractory mantle cell lymphoma.

31 efit in patients with relapsed or refractory mantle-cell lymphoma.

32 atio for ibrutinib in relapsed or refractory mantle-cell lymphoma.

33 ersus temsirolimus in relapsed or refractory mantle-cell lymphoma.

34 rituximab was active as initial therapy for mantle-cell lymphoma.

35 ibody, are active in patients with recurrent mantle-cell lymphoma.

36 ially approved for the treatment of relapsed mantle-cell lymphoma.

37 ve outcomes in patients with newly diagnosed mantle-cell lymphoma.

38 tients with chronic lymphocytic leukemia and mantle-cell lymphoma.

39 : Burkitt lymphoma, follicular lymphoma, and mantle-cell lymphoma.

40 atment option for patients with indolent and mantle-cell lymphoma.

41 l types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.

42 in 111 patients with relapsed or refractory mantle-cell lymphoma.

43 gle-agent efficacy in relapsed or refractory mantle-cell lymphoma.

44 tuximab is effective for older patients with mantle-cell lymphoma.

45 R-CHOP in patients with previously untreated mantle-cell lymphoma.

46 clinical trial of adoptive immunotherapy for mantle-cell lymphoma.

47 rity of patients with relapsed or refractory mantle-cell lymphoma.

48 imus in patients with relapsed or refractory mantle-cell lymphoma.

49 -X19 in patients with relapsed or refractory mantle-cell lymphoma.

50 vity in patients with relapsed or refractory mantle-cell lymphoma.

51 n patients with relapsed indolent B-cell and mantle cell lymphomas.

52 detectable nuclear LEF1 expression, as were mantle cell lymphoma (0 of 5), marginal zone lymphoma (0

53 mide and rituximab in patients with relapsed mantle cell lymphoma (A051201) and relapsed follicular l

54 patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic fa

55 f 56 unclustered IgH-CCND1 translocations in mantle cell lymphoma across the ~ 344-kb bcl-1 breakpoin

56 a randomised, phase 2 study of patients with mantle cell lymphoma aged 18 years or older at 67 clinic

57 ve B-cell non-Hodgkin's lymphomas, including mantle cell lymphoma and diffuse large B-cell lymphoma,

58 he BCL-2 targeting drug ABT-199 in models of mantle cell lymphoma and double-hit lymphoma evolves fro

59 , and Sept 30, 2014, 11 patients (three with mantle cell lymphoma and eight with follicular lymphoma)

60 non-Hodgkin lymphoma subtypes, in particular mantle cell lymphoma and follicular lymphoma.

61 by nonstereotyped FL BCRs and by the Igs of mantle cell lymphoma and multiple myeloma and suggest th

62 nhibitor of the UPS, bortezomib, in treating mantle cell lymphoma and multiple myeloma has demonstrat

63 Vimentin was also frequently recognized by mantle cell lymphoma and multiple myeloma Igs.

64 rash (two [67%] of three) for patients with mantle cell lymphoma and neutropenia (five [63%] of eigh

65 complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but r

66 Here, we demonstrate that adhesion of mantle cell lymphoma and other non-Hodgkin lymphoma cell

67 alignant B cells isolated from patients with mantle cell lymphoma and Waldenstrom macroglobulinemia.

68 A051201 (mantle cell lymphoma) and A051202 (follicular lymphoma)

69 seven of 15 with indolent NHL, and two with mantle-cell lymphoma) and seven of nine patients treated

70 phoma, 78% in marginal zone lymphoma, 67% in mantle cell lymphoma, and 30% in diffuse large B-cell ly

71 0) triggered synergistic cytotoxicity in MM, mantle cell lymphoma, and Burkitt lymphoma cell lines.

72 s efficiently lysed primary B-cell leukemia, mantle cell lymphoma, and multiple myeloma in vitro.

73 vity of temsirolimus in lymphomas other than mantle cell lymphoma, and supports further evaluation of

74 tment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenstrom macroglobulinemia.

75 New insights into mantle cell lymphoma biology may lead to targeted therap

76 this review is to update recent advances in mantle cell lymphoma biology with prognostic and potenti

77 2 trials have shown single-agent activity in mantle-cell lymphoma, breast cancer, liposarcoma, and te

78 than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hemato

79 ycin (mTOR) pathway is a validated target in mantle cell lymphoma, but has not been extensively evalu

80 fferentiated embryonic stem cells, B-CLL and mantle cell lymphoma, but not in major adult tissues apa

81 Here we discover neoantigens in human mantle-cell lymphomas by using an integrated genomic and

82 Thus, these results indicated that mantle cell lymphoma cell lines have distinct mechanisms

83 s in human chronic lymphocytic leukaemia and mantle cell lymphoma cell lines, and patients treated wi

84 We found that in mantle cell lymphoma cell lines, combined IKZF1/3 degrad

85 In the current study with four mantle cell lymphoma cell lines, we report a new major m

86 1s expression in wild type B cells and human mantle cell lymphoma cell lines.

87 othesised that adding rituximab could target mantle cell lymphoma cells associated with redistributio

88 ent-derived acute lymphoblastic leukemia and mantle cell lymphoma cells, whereas the IgG1 analogue wa

89 B- and mantle-cell lymphomas, chronic myeloid leukaemia, and mu

90 IMMU-114 was toxic to mantle cell lymphoma, CLL, acute lymphoblastic leukemia,

91 nrolled patients with relapsed or refractory mantle-cell lymphoma confirmed by central pathology in 2

92 Patients with a confirmed mantle cell lymphoma diagnosis (based on CD20-positive a

93 l lymphocytic lymphoma, plasma cell myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, ALK

94 ular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and

95 in a host of B-cell malignancies, including mantle cell lymphoma, diffuse large B-cell lymphoma, Wal

96 mphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma, expressed CT45.

97 e B-cell lymphoma, Richter's transformation, mantle cell lymphoma, follicular lymphoma, and chronic l

98 ls for patients with relapsed and refractory mantle cell lymphoma following prior failed Bruton's tyr

99 ed for the treatment of multiple myeloma and mantle cell lymphoma; however, in other hematologic mali

100 r treatment of relapsed multiple myeloma and mantle cell lymphoma) in dy(3K)/dy(3K) mice and in conge

101 ed specific recognition of primary B-CLL and mantle cell lymphoma, including rare drug effluxing chem

102 Patients with relapsed or refractory mantle cell lymphoma ineligible for intensive chemothera

103 tatus > 16%, lactate dehydrogenase > 1N 38%, Mantle Cell Lymphoma International Prognostic Index (low

104 The Mantle Cell Lymphoma International Prognostic Index (MIP

105 ased on the clinical factors included in the Mantle Cell Lymphoma International Prognostic Index (MIP

106 is associated with clinical characteristics (Mantle Cell Lymphoma International Prognostic Index [MIP

107 be shorter for patients presenting with high Mantle Cell Lymphoma International Prognostic Index or l

108 On the basis of the Mantle Cell Lymphoma International Prognostic Index scor

109 imilar model was created with miR-615-3p and Mantle Cell Lymphoma International Prognostic Index scor

110 I of 2, and 49% with IPI of 3 to 5), as were Mantle Cell Lymphoma International Prognostic Index scor

111 variable analysis, these risk groups and the Mantle Cell Lymphoma International Prognostic Index were

112 ostic value of miR-29 is comparable with the Mantle Cell Lymphoma International Prognostic Index.

113 ignificantly different OS independent of the Mantle Cell Lymphoma International Prognostic Index.

114 tratified by previous therapy and simplified mantle-cell lymphoma international prognostic index scor

115 Mantle cell lymphoma is a B cell malignancy in which con

116 Mantle cell lymphoma is a generally incurable disease fo

117 Purpose Mantle cell lymphoma is an aggressive B-cell neoplasm th

118 Mantle cell lymphoma is characterized by a particularly

119 Mantle cell lymphoma is characterized by dysregulation o

120 Mantle-cell lymphoma is an aggressive B-cell lymphoma wi

121 Mantle-cell lymphoma is generally incurable.

122 long-term prognosis for older patients with mantle-cell lymphoma is poor.

123 or bortezomib-resistant, relapsed/refractory mantle-cell lymphoma, lenalidomide has demonstrated effi

124 aluating this compound in four proliferating mantle cell lymphoma lines (Jeko-1, Granta 519, Mino, an

125 of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma, marginal zone lymphoma and Sezary

126 ollicular lymphoma (FL) (16.3% [43 of 263]), mantle cell lymphoma (MCL) (6.8% [18 of 263]), and diffu

127 large B-cell lymphoma (DLBCL) (10% [n = 9]), mantle cell lymphoma (MCL) (8% [n = 7]), and mycosis fun

128 follicular lymphoma (FL) (11%, n = 91), and mantle cell lymphoma (MCL) (8%, n = 66).

129 e B-cell lymphoma (DLBCL) (n = 25, 10%), and mantle cell lymphoma (MCL) (n = 17, 7%).

130 Mantle cell lymphoma (MCL) accumulates in lymphoid organ

131 ignancy that may be hard to distinguish from mantle cell lymphoma (MCL) and chronic lymphocytic leuke

132 broad panel of lymphoma cell lines including mantle cell lymphoma (MCL) and diffuse large B-cell lymp

133 ate the therapeutic efficacy of atiprimod on mantle cell lymphoma (MCL) and elucidate the mechanism b

134 CLL), T-prolymphocytic leukemia (T-PLL), and mantle cell lymphoma (MCL) and is associated with defect

135 nti-CD74 IgG)] show enhanced cytotoxicity in mantle cell lymphoma (MCL) and other lymphoma/leukemia c

136 ouse model, we demonstrated that adhesion of mantle cell lymphoma (MCL) and other non-Hodgkin lymphom

137 monstrated in tumors derived from Granta-519 mantle cell lymphoma (MCL) and Raji Burkitt lymphoma (BL

138 In mantle cell lymphoma (MCL) and some cases of multiple my

139 We used mantle cell lymphoma (MCL) as a prototypic blood cancer

140 Y-box 11 (SOX11) expression is specific for mantle cell lymphoma (MCL) as compared with other non-Ho

141 tivation of the translocated CCND1 allele in mantle cell lymphoma (MCL) because of its relocalization

142 et al describe recurrent NOTCH1 mutations in mantle cell lymphoma (MCL) by next-generation sequencing

143 Mantle cell lymphoma (MCL) carries an unfavorable progno

144 ut primary chronic lymphocytic leukaemia and mantle cell lymphoma (MCL) cells are resistant.

145 Mantle cell lymphoma (MCL) cells exhibit increased B-cel

146 hibits enhanced antiproliferative effects on mantle cell lymphoma (MCL) cells in vitro by degrading B

147 with the tumor microenvironment account for mantle cell lymphoma (MCL) cells survival in lymphoid or

148 ivery of a nucleotide antagonist of eIF4E in mantle cell lymphoma (MCL) cells.

149 of NF-kappaB and chemotherapy resistance in mantle cell lymphoma (MCL) cells.

150 nel of lymphoid cancer cell lines as well as mantle cell lymphoma (MCL) clinical samples.

151 e randomized, open-label, phase III European Mantle Cell Lymphoma (MCL) Elderly trial (ClinicalTrials

152 Recent studies show that mantle cell lymphoma (MCL) express aberrant microRNA (mi

153 Mantle cell lymphoma (MCL) has a chromosomal translocati

154 SOX11 overexpression in mantle cell lymphoma (MCL) has been associated with more

155 blood-brain barrier and has activity against mantle cell lymphoma (MCL) in the central nervous system

156 cell leukemia (HCL) cases, 15% (5 of 34) of mantle cell lymphoma (MCL) in the leukemic phase, and 16

157 interrogate signaling pathways activated in mantle cell lymphoma (MCL) in vivo, we contrasted gene e

158 Treatment of mantle cell lymphoma (MCL) in younger patients remains a

159 Mantle cell lymphoma (MCL) is a B-cell lymphoma characte

160 Mantle cell lymphoma (MCL) is a B-cell malignancy charac

161 Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymph

162 Mantle cell lymphoma (MCL) is a distinct subtype of non-

163 Mantle cell lymphoma (MCL) is a heterogeneous disease wi

164 Mantle cell lymphoma (MCL) is a highly aggressive B-cell

165 Mantle cell lymphoma (MCL) is a mature B-cell lymphoma c

166 Mantle cell lymphoma (MCL) is a mature B-cell malignancy

167 Mantle cell lymphoma (MCL) is a mature B-cell neoplasm i

168 Mantle cell lymphoma (MCL) is a mostly incurable maligna

169 Mantle cell lymphoma (MCL) is a rare and aggressive form

170 Mantle cell lymphoma (MCL) is a unique type of non-Hodgk

171 Mantle cell lymphoma (MCL) is an aggressive and incurabl

172 Mantle cell lymphoma (MCL) is an aggressive B cell lymph

173 Mantle cell lymphoma (MCL) is an aggressive B-cell malig

174 Mantle cell lymphoma (MCL) is an aggressive B-cell malig

175 Mantle cell lymphoma (MCL) is an aggressive B-cell non-H

176 Mantle cell lymphoma (MCL) is an aggressive malignancy t

177 Mantle cell lymphoma (MCL) is an aggressive tumor, but a

178 ion signature of tumor proliferation rate in mantle cell lymphoma (MCL) is an overriding molecular pr

179 Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hod

180 Mantle cell lymphoma (MCL) is an uncommon subtype of non

181 t failure (TTF) and overall survival (OS) in mantle cell lymphoma (MCL) is based on the clinical fact

182 Mantle cell lymphoma (MCL) is characterized by a profoun

183 Mantle cell lymphoma (MCL) is characterized by an aggres

184 Mantle cell lymphoma (MCL) is characterized by an early,

185 Mantle cell lymphoma (MCL) is characterized by the t(11;

186 Mantle cell lymphoma (MCL) is characterized by the uncon

187 ic role of the transcription factor SOX11 in mantle cell lymphoma (MCL) is controversial.

188 entral nervous system (CNS) dissemination in mantle cell lymphoma (MCL) is low and occurs late in the

189 Mantle cell lymphoma (MCL) is one of the most aggressive

190 Mantle cell lymphoma (MCL) is one of the most aggressive

191 ed CD19+/CD20+/CD45+ human lymphoma cells in mantle cell lymphoma (MCL) JeKo-1 model, while the same

192 (D), and 4-hydroxycyclophosphamide (4-HC) in mantle cell lymphoma (MCL) lines.

193 Mantle cell lymphoma (MCL) may be 1 of the few cancers f

194 ase (PI3K) pathway activation contributes to mantle cell lymphoma (MCL) pathogenesis, but early-phase

195 as identified a number of novel mutations in mantle cell lymphoma (MCL) patients including mutations

196 matic gene copy number alterations (CNAs) in mantle cell lymphoma (MCL) patients treated first line w

197 , display remarkable activity in a subset of mantle cell lymphoma (MCL) patients, but the drug resist

198 spite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains incurable, and we are

199 tioning regimen on outcome for patients with mantle cell lymphoma (MCL) remains unknown.

200 There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immu

201 is study, we define the genetic landscape of mantle cell lymphoma (MCL) through exome sequencing of 5

202 cently reported the application of RNAseq to mantle cell lymphoma (MCL) transcriptomes revealing recu

203 tween chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) tumors.

204 Patients with mantle cell lymphoma (MCL) typically respond to initial

205 opoiesis in serial samples from persons with mantle cell lymphoma (MCL) undergoing frontline treatmen

206 Mantle cell lymphoma (MCL) usually responds well to init

207 rosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior t

208 ent study, we analyzed telomere length in 73 mantle cell lymphoma (MCL), 55 chronic lymphocytic leuke

209 thesized that 8-NH(2)-Ado would be active in mantle cell lymphoma (MCL), a hematological malignancy c

210 Mantle cell lymphoma (MCL), an aggressive subtype of non

211 randomized trials have compared therapies in mantle cell lymphoma (MCL), and the role of aggressive i

212 SOX11 is usually highly expressed in typical mantle cell lymphoma (MCL), but it is absent in the more

213 nt in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), but the extent of internaliz

214 lymphoma (FL), and (3) other NHL, including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL)

215 In mantle cell lymphoma (MCL), one allele of the cyclin D1

216 is clinically approved for the treatment of mantle cell lymphoma (MCL), only limited effects of this

217 Despite unprecedented clinical activity in mantle cell lymphoma (MCL), primary and acquired resista

218 ediated effects of interleukin-21 (IL-21) in mantle cell lymphoma (MCL), providing a preclinical rati

219 advances in the therapy for newly diagnosed mantle cell lymphoma (MCL), relapsed MCL continues to ha

220 For elderly patients with mantle cell lymphoma (MCL), there is no defined standard

221 r understanding about antigen involvement in mantle cell lymphoma (MCL), we analyzed the expression l

222 To obtain insight into the ontogeny of mantle cell lymphoma (MCL), we assessed 206 patients fro

223 mong 45 patients with relapsed or refractory mantle cell lymphoma (MCL), with manageable tolerability

224 comes for ibrutinib-refractory patients with mantle cell lymphoma (MCL).

225 se large B-cell lymphoma (DLCL), and 17 with mantle cell lymphoma (MCL).

226 clinical course of the human SOX11-negative mantle cell lymphoma (MCL).

227 ling 40 patients with relapsed or refractory mantle cell lymphoma (MCL).

228 agents for relapsed/refractory patients with mantle cell lymphoma (MCL).

229 b, we noted similar effects in patients with mantle cell lymphoma (MCL).

230 overexpressed in B-cell malignancies such as mantle cell lymphoma (MCL).

231 n has been implicated in the pathogenesis of mantle cell lymphoma (MCL).

232 demonstrated miR-15a/16-1 downregulation in mantle cell lymphoma (MCL).

233 nib in both chronic lymphocytic leukemia and mantle cell lymphoma (MCL).

234 val in non-Hodgkin lymphoma (NHL), except in mantle cell lymphoma (MCL).

235 th diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

236 issions in 30%-50% of patients with relapsed mantle cell lymphoma (MCL).

237 etan in patients with relapsed or refractory mantle cell lymphoma (MCL).

238 the t(11;14)(q13;q32) translocation found in mantle cell lymphoma (MCL).

239 eukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

240 treating selected NHL, including aggressive mantle cell lymphoma (MCL).

241 70% of patients with relapsed and refractory mantle cell lymphoma (MCL).

242 atment for patients with relapsed/refractory mantle cell lymphoma (MCL).

243 s active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all

244 oxidative stress-mediated drug resistance in mantle cell lymphoma (MCL); however, the biological func

245 mall lymphocytic lymphoma (CLL/SLL; n = 15), mantle cell lymphoma (MCL; n = 15), low-grade follicular

246 Results NHL subtypes included mantle cell lymphoma (MCL; n = 28), follicular lymphoma

247 co purified DNA methylation signatures of 82 mantle cell lymphomas (MCL) in comparison with cell subp

248 Mantle-cell lymphoma (MCL) has a variable natural histor

249 omide has shown promise for the treatment of mantle-cell lymphoma (MCL) in preclinical studies.

250 Mantle-cell lymphoma (MCL) is a distinct B-cell lymphoma

251 Mantle-cell lymphoma (MCL) is a rather aggressive B-cell

252 PURPOSE Mantle-cell lymphoma (MCL) is an aggressive B-cell non-H

253 Treatment of mantle-cell lymphoma (MCL) is nonstandardized, though pa

254 an diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL) xenograft models.

255 rabine, and rituximab (FFR) in patients with mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin'

256 have improved the outcome for patients with mantle-cell lymphoma (MCL), most eventually relapse and

257 ctory diffuse large B-cell lymphoma (DLBCL), mantle-cell lymphoma (MCL), transformed follicular lymph

258 ) is efficacious, with favorable toxicity in mantle-cell lymphoma (MCL).

259 attempt to improve outcome in patients with mantle-cell lymphoma (MCL); however, the importance of i

260 Blastoid-variant mantle-cell lymphoma (MCL-BV), unlike most B-cell non-Ho

261 Cyclin D1(-) mantle cell lymphomas (MCLs) are not well characterized,

262 umors and in the vast majority of aggressive mantle cell lymphomas (MCLs).

263 sk chronic lymphocytic leukemia (n = 22) and mantle-cell lymphoma (n = 13) received a total lymphoid

264 gkin lymphoma (n=83), and 37% in indolent or mantle-cell lymphoma (n=65).

265 y drug (chronic lymphocytic leukaemia, n=21; mantle cell lymphoma, n=21).

266 dge, the clinical features of ocular adnexal mantle-cell lymphoma (OA-MCL) have not previously been e

267 a dramatically regressed, and a patient with mantle cell lymphoma obtained an ongoing partial remissi

268 y high-risk chronic lymphocytic leukaemia or mantle cell lymphoma often do not derive durable benefit

269 patients with diffuse large B-cell lymphoma, mantle-cell lymphoma, or follicular lymphoma were enroll

270 LBCL (P(trend) = 0.02) and IL10 -1082A>G and mantle cell lymphoma (P(trend) = 0.04).

271 t trials with these agents were conducted in mantle cell lymphoma, pancreatic neuroendocrine tumors a

272 tumor biopsies were reviewed by the European Mantle Cell Lymphoma Pathology Panel to determine Ki-67

273 In mantle cell lymphoma patient samples, we found that lowe

274 One hundred sixty untreated, stage II-IV mantle cell lymphoma patients <66 years received rituxim

275 patients were 73% and 47%, respectively; for mantle-cell lymphoma patients, they were 69% and 53%, re

276 large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, and no

277 Patients with previously untreated mantle cell lymphoma received VcR-CVAD chemotherapy ever

278 small molecule inhibitor (HDACi) in CLL and mantle cell lymphoma restored the expression of the BTK-

279 stochemical analysis of a cohort of 33 human mantle cell lymphomas shows that elevated expression of

280 igned patients 60 years of age or older with mantle-cell lymphoma, stage II to IV, who were not eligi

281 rapeutic agent for multiple myeloma (MM) and mantle cell lymphoma, suppresses proteosomal degradation

282 nd potentially therapeutic implications, and mantle cell lymphoma treatment approaches and new agents

283 chronic lymphocytic leukaemia or 560 mg for mantle cell lymphoma) until disease progression or unacc

284 iven to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacc

285 mphocytic leukemia, follicular lymphoma, and mantle cell lymphoma were 5%-10% higher per 5-year incre

286 71 patients with mantle cell lymphoma were enrolled and 69 were assessabl

287 16, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients rece

288 ed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cell

289 Thirty patients (7 with mantle cell lymphoma) were enrolled and treated.

290 Z138 cells, a B cell line derived from human mantle cell lymphoma, were infused i.v. or s.c.

291 ents with histologically documented relapsed mantle cell lymphoma who had not received previous lenal

292 , USA, and other countries for patients with mantle cell lymphoma who received one previous therapy.

293 e I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission afte

294 Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during

295 mly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not consider

296 al, and overall survival among patients with mantle-cell lymphoma who were younger than 66 years of a

297 nts with relapsed or refractory indolent and mantle cell lymphoma with adequate organ function were t

298 een reported in patients with follicular and mantle-cell lymphoma with the combination of bendamustin

299 refractory chronic lymphocytic leukaemia and mantle cell lymphoma, with a recommended phase 2 dose of

300 refractory chronic lymphocytic leukaemia or mantle cell lymphoma, with an Eastern Cooperative Oncolo